Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." ?g. }

• _6 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
• _6 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
• _4 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
• _6 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
• _6 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.
• _4 value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6?8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." provenance.